Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -3.43%12 Cash-to-Debt is 4.20 as of Apr. 2026, which is 60% above its 10-year median of 2.63. GuruFocus rates KMTS with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 63.37% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kestra Medical Technologies's cash to debt ratio for the quarter that ended in Apr. 2026 was 4.20.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kestra Medical Technologiescould pay off its debt using the cash in hand for the quarter that ended in Apr. 2026.
The historical rank and industry rank for Kestra Medical Technologies's Cash-to-Debt or its related term are showing as below:
KMTS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: 2.63 Max: 12.74
Current: 4.2
During the past 6 years, Kestra Medical Technologies's highest Cash to Debt Ratio was 12.74. The lowest was 0.18. And the median was 2.63.
KMTS's Cash-to-Debt is ranked better than 63.37% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs KMTS: 4.20
Kestra Medical Technologies (NAS:KMTS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Kestra Medical Technologies Cash-to-Debt Related Terms
Kestra Medical Technologies Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a Cash-to-Debt of 4.20 as of Apr. 2026. This is 60% above median its historical median of 2.63. Over the past decade, Kestra Medical Technologies' Cash-to-Debt has ranged from 0.18 to 12.74. According to the industry distribution chart, Kestra Medical Technologies ranks #311 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 36.6%.
Is Kestra Medical Technologies' Cash-to-Debt too high?
Kestra Medical Technologies' current Cash-to-Debt of 4.20 is 60% above median its 10-year median of 2.63. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 12.74. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Kestra Medical Technologies' value of 4.20 is 156.1% above this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #311 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Cash-to-Debt compare to AZTA and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #311 out of 849 companies for Cash-to-Debt. This puts Kestra Medical Technologies in the upper half of its industry. The industry median Cash-to-Debt is 1.64. Kestra Medical Technologies' value of 4.20 is 156.1% above this benchmark. Historically, Kestra Medical Technologies' own Cash-to-Debt has ranged from 0.18 to 12.74 over the past decade. While the company's 10-year median is 2.63 vs. the industry median of 1.64, Kestra Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Cash-to-Debt of 4.20 is 156.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Cash-to-Debt is 4.20, which is 60% above median its own 10-year median of 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Cash-to-Debt of 4.20. The current Cash-to-Debt is 4.20, which is 60% above median its 10-year median of 2.63 and 156.1% above the Medical Devices & Instruments industry median of 1.64. Kestra Medical Technologies' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Cash-to-Debt is 4.20 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
12GF Score
Get the complete analysis for KMTS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
